AMLX Stock Quote Price and Forecast | CNN

AMLX

Amylyx Pharmaceuticals, Inc.

Key terms

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Key terms

Smart score

Apr 16 5:32am ET Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM) by TipRanks Apr 12 1:39am ET Amylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial Results by TipRanks Apr 11 6:31am ET Amylyx price target lowered to $3 from $4 at Baird by TipRanks Apr 10 1:15pm ET Amylyx to hold a conference call by TipRanks Apr 08 6:16am ET Optimistic Outlook for Amylyx Pharmaceuticals Inc with AMX0035’s Potential in Rare Diseases by TipRanks Apr 08 4:25am ET Amylyx Pharmaceuticals Shifts Focus: Hold Recommendation Amidst R&D Pivot and Revenue Impact by TipRanks Apr 05 4:57am ET Amylyx Pharmaceuticals Hold Rating: Navigating Setbacks with a Strategic Pivot and Long-Term Potential by TipRanks Apr 04 3:15pm ET Amylyx Pharmaceuticals: Hold Rating Maintained Amidst Drug Discontinuation and Pipeline Developments by TipRanks Apr 04 7:22am ET Amylyx Pharmaceuticals Enacts Major Restructuring and Refocuses Strategy by TipRanks Apr 04 7:05am ET Amylyx will reduce workforce by 70% by TipRanks Apr 04 7:05am ET Amylyx announces formal intention to remove RELYVRIO/ALBRIOZA from market by TipRanks Mar 29 4:25am ET Impact of Clinical Setbacks on Amylyx Pharmaceuticals: A Hold Rating Amidst Market Uncertainty by TipRanks Mar 27 4:15pm ET Amylyx Pharmaceuticals: Hold Rating Maintained Amidst Development Shifts and Trial Setbacks by TipRanks Mar 22 3:37am ET Class Action against Amylyx Pharmaceuticals Inc. (AMLX) by TipRanks Mar 19 9:40am ET Unusually active option classes on open March 19th by TipRanks Mar 17 3:55pm ET Maintaining Hold on Amylyx Pharmaceuticals Post-PHOENIX Study Setback and Relyvrio Uncertainties by TipRanks Mar 17 3:41pm ET Amylyx downgraded to Neutral from Buy at Mizuho by TipRanks Mar 14 9:33am ET Amylyx Pharmaceuticals Appoints New Board Member for 2025 Term by TipRanks Mar 12 6:10am ET Amylyx price target lowered to $8 from $42 at H.C. Wainwright by TipRanks Mar 11 9:57am ET Disney initiated, Foot Locker upgraded: Wall Street’s top analyst calls by TipRanks Mar 11 6:37am ET Baird downgrades Amylyx, sees Relyvrio being withdrawn soon by TipRanks Mar 11 6:18am ET Amylyx downgraded to Market Perform from Outperform at Leerink by TipRanks Mar 11 5:07am ET Amylyx downgraded to Neutral from Outperform at Baird by TipRanks Mar 11 4:37am ET Amylyx selloff on study miss overdone, says Deutsche Bank by TipRanks Mar 11 12:55am ET Evaluating Amylyx Pharmaceuticals: A Buy Rating Amidst PHOENIX Study Anticipation by TipRanks Mar 08 1:45pm ET Amylyx downgraded to Neutral from Buy at Goldman Sachs by TipRanks Mar 08 1:45pm ET Hold Rating on Amylyx Pharmaceuticals Amid Relyvrio Trial Setbacks and Revenue Uncertainty by TipRanks Mar 08 11:30am ET Amylyx Pharmaceuticals trading resumes by TipRanks Mar 08 11:25am ET Amylyx Pharmaceuticals trading halted, volatility trading pause by TipRanks Mar 08 9:39am ET Amylyx drops 85% after ALS trial did not meet primary endpoint by TipRanks Mar 08 9:29am ET Amylyx reports PHOENIX ALS trial did not meet primary endpoint by TipRanks

Apr 09 5:32pm ET FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx by Newsfile Apr 09 12:45pm ET April 9, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AMLX by Accesswire Apr 09 11:00am ET Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX by Accesswire Apr 09 7:30am ET Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline by Accesswire Apr 09 7:00am ET FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm by Accesswire Apr 09 5:00am ET Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky by Accesswire Apr 08 7:00pm ET Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX by Accesswire Apr 08 5:51pm ET AMLX FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action by Newsfile Apr 08 1:10pm ET 48 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx by Newsfile Apr 08 11:45am ET Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX by Accesswire Apr 08 10:45am ET Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline by Accesswire Apr 08 7:30am ET Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline by Accesswire Apr 08 7:00am ET FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm by Accesswire Apr 08 4:40am ET Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX by Accesswire Apr 07 6:00pm ET AMLX FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX by Newsfile Apr 07 7:46am ET DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx by Newsfile Apr 06 5:40pm ET AMLX FINAL DEADLINE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX by Newsfile Apr 06 9:16am ET SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - AMLX by Newsfile Apr 06 7:33am ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx by Newsfile Apr 05 5:39pm ET AMLX FINAL DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX by Newsfile Apr 05 11:18am ET Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint - Hagens Berman by Newsfile Apr 05 8:08am ET Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX) as Company Formally Pulls Relyvrio from the Market by Newsfile Apr 03 6:00pm ET AMLX DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX by Newsfile Apr 02 5:59pm ET AMLX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX by Newsfile Apr 02 5:43pm ET ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx by Newsfile Apr 02 4:04pm ET AMLX 1-WEEK DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action by Newsfile Apr 01 5:32pm ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx by Newsfile Apr 01 4:11pm ET AMLX DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX by Newsfile Mar 30 9:08pm ET TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX by Newsfile Mar 30 8:47am ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx by Newsfile Mar 29 9:08pm ET ROSEN, LEADING TRIAL ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX by Newsfile

1-year income & revenue

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Meta headquarters pictured on February 02, 2023 in Menlo Park, California.

Justin Sullivan/Getty Images

Meta’s stock plunges 15% on ‘aggressive’ AI spending plans

GettyImages-1159438448 copy.jpg

Lyndon Stratford/iStockphoto/Getty Images

Americans are falling behind on their payments

Arnd Wiegmann/Reuters

Switzerland says UBS may need more cash. The bank is fuming

Jamie Dimon, Chairman and Chief Executive officer (CEO) of JPMorgan Chase & Co. (JPM) speaks to the Economic Club of New York in Manhattan in New York City, U.S., April 23, 2024. REUTERS/Mike Segar

Mike Segar/Reuters

Jamie Dimon fears for the future of the free world and US debt